ArchiveAugust 2015

ClinicSpeak: glatiramer acetate experience and persistence

Glatiramer acetate, Teva’s cash-cow, has plenty of life left in it! #ClinicSpeak #MSBlog #MSResearch “I am often asked is there a future for the injectable DMTs. My knee jerk response is yes; the injectables are safe and there a large number of responders out there who will almost certainly want to stay on their current medication. Why? There is no data suggesting that if you are a...

Fingolimod in the real world

Totaro R, Di Carmine C, Costantino G, Fantozzi R, Bellantonio P, Fuiani A, Mundi C, Ruggieri S, Marini C, Carolei A. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.Mult Scler Int. 2015;2015:763418. doi: 10.1155/2015/763418. Objective. The aim of this prospective observational multicenter postmarketing study was...

Cell migration in Remyelination

Harlow DE, Saul KE, Komuro H, Macklin WB. Myelin Proteolipid Protein Complexes with αv Integrin and AMPA Receptors In Vivo and Regulates AMPA-Dependent Oligodendrocyte Progenitor Cell Migration through the Modulation of Cell-Surface GluR2 Expression. J Neurosci. 2015;35(34):12018-12032. In previous studies, stimulation of ionotropic AMPA/kainate glutamate receptors on cultured...

GABA as a neuroprotectant

Cawley N, Solanky BS, Muhlert N, Tur C, Edden RA, Wheeler-Kingshott CA, Miller DH, Thompson AJ, Ciccarelli O Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressivemultiple sclerosis.Brain. 2015;138(Pt 9):2584-95. doi: 10.1093/brain/awv209. Neurodegeneration is thought to be the major cause of ongoing, irreversible disability in progressive stages of...

ClinicSpeak: wrists weights work for cerebellar tremors

How good is your hand function? Do you need wrist weights? #ClinicSpeak #MSBlog #MSResearch “The small study below in MSers with so called cerebellar tremor may be of interest to you. The cerebellum or ‘small brain’ is the structure at the back of your brain that controls motor function. It is commonly affected in MS and results in uncoordinated and slow movements...

imaging grey matter loss

Freeman L, Garcia-Lorenzo D, Bottin L, Leroy C, Louapre C, Bodini B, Papeix C, Assouad R, Granger B, Tourbah A, Dollé F, Lubetzki C, Bottlaender M, Stankoff B. The neuronal component of gray matter damage in multiple sclerosis: A [11C]-flumazenil positron emission tomography study.Ann Neurol. 2015 Aug. doi: 10.1002/ana.24468 OBJECTIVE:Using positron emission tomography (PET) with [11 C]flumazenil...

Co-ordinated production and loss of factors are needed for remyelination

Zhao C, Ma D, Zawadzka M, Fancy SP, Elis-Williams L, Bouvier G, Stockley JH, de Castro GM, Wang B, Jacobs S, Casaccia P, Franklin RJ. Sox2 Sustains Recruitment of Oligodendrocyte Progenitor Cells following CNS Demyelination and Primes Them for Differentiation during Remyelination. J Neurosci. 2015 19; 35:11482-99.  The Sox family of transcription factors have been widely studied in...

ResearchSpeak: Vitamin D and MS risk

The best time to plant a tree is twenty years ago. The second best time is now. #ResearchSpeak #MSBlog #MSResearch “The study below on vitamin D (vD) and MS risk confirms what we already know that low vD levels increase your risk of getting MS. What is really very neat is how the investigators’ did this study; they used a very cool method called Mendelian Randomization. Yes, Mendelian...

Low L-selectin as a risk factor for PML

Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells. J Neuroinflammation. 2015 Aug;12(1):146. doi: 10.1186/s12974-015-0365-x. BACKGROUND: The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of...

Improved walking with medical cannabis

Coghe G, Pau M, Corona F, Frau J, Lorefice L, Fenu G, Spinicci G, Mamusa E, Musu L, Massole S, Massa R, Marrosu MG, Cocco E.J Walking improvements with nabiximols in patients with multiple sclerosis. Neurol. 2015 Aug 5. [Epub ahead of print] Recently, nabiximols was approved as a treatment in MS spasticity. Data leading to approval and clinical use of nabiximols, although widely...

Translate

Categories

Recent Posts

Recent Comments

Archives